The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease

No abstract is available for this paper.

• Publication year

  2003

• Venue

  European Journal of Neurology

• Publication date

  2003-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1468-1331.2003.00559.xPMID 12603288
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Irreversible motor impairment in young addicts – ephedrone, manganism or both?

  2007cited by this paper
• Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study

  2003cited by this paper
• Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study)

  2002influential reference
• Treatment interventions for Parkinson's disease: an evidence based assessment.

  2002cited by this paper
• Levodopa prolongs life expectancy and is non-toxic to substantia nigra.

  2001cited by this paper
• Efficacy and Tolerability of Entacapone as Adjunctive Therapy to Levodopa in Patients with Parkinson’s Disease and End-of-Dose Deterioration in Daily Medical Practice: An Open, Multicenter Study

  2001cited by this paper
• Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat

  2001cited by this paper
• Twelve‐month safety of entacapone in patients with Parkinson’s disease

  2001influential reference
• [The Unified Parkinson's Disease Rating Scale].

  2000cited by this paper
• COMT inhibitors and liver toxicity.

  2000cited by this paper
• Continuous dopamine-receptor stimulation in early Parkinson's disease.

  2000cited by this paper
• Continuous dopamine-receptor stimulation in advanced Parkinson's disease.

  2000cited by this paper
• Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.

  2000cited by this paper
• The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease

  2000cited by this paper
• Quality of life as a predictor for change in disability in MS

  2000cited by this paper
• Preventing levodopa-induced dyskinesias.

  2000cited by this paper
• Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson’s Disease

  2000cited by this paper
• Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase.

  1999cited by this paper
• Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations

  1998influential reference
• The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score.

  1997cited by this paper
• Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production.

  1997cited by this paper
• Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patients

  1997cited by this paper
• Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.

  1996cited by this paper
• Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.

  1996cited by this paper
• A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.

  1996cited by this paper
• The response to levodopa in parkinson's disease: Imposing pharmacological law and order

  1996cited by this paper
• A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.

  1996cited by this paper
• Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.

  1996cited by this paper
• Entacapone in combination with standard or controlled‐release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease

  1995cited by this paper
• Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the short-form health survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39)

  1995cited by this paper
• Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

  1994influential reference
• Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.

  1994cited by this paper
• General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.

  1994influential reference
• Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans.

  1993cited by this paper
• Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease.

  1990cited by this paper
• "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

  1976cited by this paper
• Parkinsonism

  1967cited by this paper

• The possible protective effect of entacapone on hepatic fibrosis via the fat mass and obesity-associated protein/ N6-methyladenosine/ silent information regulator 1 pathway in a rat model.

  2025cites this paper
• Safety of COMT-inhibitors in parkinson's disease: a phase-IV comparative study on adverse events of Tolcapone, Entacapone and Opicapone.

  2025cites this paper
• Levodopa/carbidopa/entacapone versus levodopa/benserazide plus pramipexole in Chinese patients with Parkinson’s disease experiencing wearing off

  2025cites this paper
• Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations

  2023cites this paper
• Catechol‐O‐methyltransferase inhibition with entacapone: Evidence from controlled clinical trials in Parkinson's disease

  2023cites this paper
• Opicapone versus entacapone: Head‐to‐head retrospective data‐based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol‐O‐methyltransferase (COMT) inhibitor treatment

  2023cites this paper
• Effective Management of “OFF” Episodes in Parkinson’s Disease: Emerging Treatment Strategies and Unmet Clinical Needs

  2023cites this paper
• Allucinazioni e morbo di Parkinson

  2022cites this paper
• COMT Inhibitors in the Management of Parkinson’s Disease

  2022cites this paper
• Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease

  2021cites this paper
• Hallucinations et maladie de Parkinson

  2021cites this paper
• Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

  2020cites this paper
• Levodopa/carbidopa/entacapone for the treatment of early Parkinson’s disease: a meta-analysis

  2020cites this paper
• Effects of Drugs and Excipients on Hydration Status

  2019cites this paper
• Contemporary Options for the Management of Motor Complications in Parkinson’s Disease: Updated Clinical Review

  2019cites this paper
• Safety Profile of Opicapone in the Management of Parkinson’s Disease

  2019cites this paper
• Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial

  2017cites this paper
• Old and new challenges in Parkinson's disease therapeutics

  2017cites this paper
• Treatment for Dementia: Learning from Breakthroughs for Other Conditions.

  2016cites this paper
• The efficacy of Levodopa+DDC inhibitor+Entacapone versus Levodopa+DDC inhibitor+Placebo in Parkinson's disease: an intervention review

  2015cites this paper
• Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson’s disease

  2014cites this paper
• Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson’s disease experiencing mild wearing-off: a randomised, double-blind trial

  2014cites this paper
• Allucinazioni e malattia di Parkinson

  2014cites this paper
• Wykładniki ciśnienia tętniczego w chorobach zwyrodnieniowych układu nerwowego

  2014cites this paper
• Specificity and sensibility of 9-Itens Wearing-off Questionnaire in Brazilian Parkinson disease patient sample.

  2014cites this paper
• [Nocturnal symptoms of Parkinson's disease and approaches to their correction].

  2013cites this paper
• Catechol-O-methyltransferase and pain in rodents and humans

  2013influential citation
• Hallucinations et maladie de Parkinson

  2013cites this paper
• Catechol-O-methyltransferase inhibitors

  2013cites this paper
• Update in Parkinson’s Disease

  2012cites this paper
• Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment.

  2012cites this paper
• A Systematic Review of Catechol-O-Methyltransferase Inhibitors: Efficacy and Safety in Clinical Practice

  2012cites this paper
• Développement d'un modèle animal chez le rat reproduisant un déficit motivationnel pouvant s'apparenter à un syndrome d'apathie de la maladie de Parkinson

  2012influential citation
• 1 Update in Parkinson ’ s Disease

  2012cites this paper
• Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson’s disease: focus on levodopa/carbidopa/entacapone

  2012cites this paper
• Immediate Versus Delayed Switch From Levodopa/Carbidopa to Levodopa/Carbidopa/Entacapone: Effects on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-Dose Wearing Off

  2011cites this paper
• Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.

  2011cites this paper
• [Treatment of non-motor fluctuations with combined drug stalevo in patients with Parkinson's disease].

  2011cites this paper
• Erythrocytes Catechol-O-Methyl Transferase Activity Is Up-Regulated After a 3-Month Treatment by Entacapone in Parkinsonian Patients

  2011cites this paper
• The Association between Adherence to Levodopa/Carbidopa/Entacapone Therapy and Healthcare Utilization and Costs among Patients with Parkinson’s Disease

  2011cites this paper
• Differential effects of COMT on gait and executive control in aging.

  2010cites this paper
• The Impact of Levodopa on Quality of Life in Patients With Parkinson Disease

  2010cites this paper
• Levodopa in the treatment of Parkinson’s disease: an old drug still going strong

  2010cites this paper
• Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson’s disease

  2010cites this paper
• Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.

  2010cites this paper
• Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis

  2009cites this paper
• Levodopa/carbidopa/entacapone in Parkinson’s disease

  2009cites this paper
• Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference

  2009cites this paper
• The scientific and clinical basis for the treatment of Parkinson disease (2009)

  2009cites this paper
• Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson’s Disease

  2008cites this paper
• Is There a Difference between Levodopa/ Dopa-Decarboxylase Inhibitor and Entacapone and Levodopa/Dopa-Decarboxylase Inhibitor Dose Fractionation Strategies in Parkinson’s Disease Patients Experiencing Symptom Re-Emergence due to Wearing-Off?

  2008cites this paper
• Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective

  2008influential citation
• Levodopa: Past, Present, and Future

  2008cites this paper
• Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson’s disease

  2008cites this paper
• Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort

  2008cites this paper
• Long‐term retention rate of entacapone in the treatment of Parkinson’s disease

  2008cites this paper
• [The clinical-pharmacoeconomic study of efficacy of stalevo in the treatment of Parkinson's disease with motor fluctuations].

  2008cites this paper
• Pharmacologic Options for Treatment of Levodopa-Associated ``Wearing Off''

  2008cites this paper
• Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.

  2007cites this paper
• Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease

  2007cites this paper
• One-Year Open-Label Study of Entacapone in Patients with Advanced Parkinson Disease

  2007cites this paper
• Long‐term effectiveness and quality of life improvement in entacapone‐treated Parkinson's disease patients: the effects of an early therapeutic intervention

  2007cites this paper
• The effects of entacapone on cardiorespiratory, autonomic, and clinical responses in L-dopa-treated patients with Parkinson's disease

  2006cites this paper
• Levodopa/carbidopa/entacapone for the treatment of Parkinson's disease

  2006cites this paper
• [The current approaches to diagnostics and therapy of fluctuations in Parkinson's disease].

  2006cites this paper
• [Stalevo (levodopa/carbidopa/entacapon)--a new generation drug in the treatment of Parkinson's disease].

  2006cites this paper
• Patient satisfaction with switching to Stalevo: an open‐label evaluation in PD patients experiencing wearing‐off (Simcom Study)

  2006cites this paper
• Modifications neurochimiques au sein des ganglions de la base et comportements moteurs associés lors d'une stimulation électrique du noyau subthalamique chez le rat hémiparkinsonien ou de la mise en place de la dénervation dopaminergique chez le singe

  2006cites this paper
• Efficacy and Safety of Entacapone in the Patients with Parkinson's Disease Experiencing Wearing-off Phenomenon: Multicenter Randomized Placebo-controlled Double Blind Study

  2005cites this paper
• Entacapone in the treatment of Parkinson's disease.

  2005cites this paper
• Medicine‐taking behavior: Implications of suboptimal compliance in Parkinson's disease

  2005cites this paper
• Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo*) compared to standard care in UK Parkinson's disease patients with wearing-off

  2005cites this paper
• Treatment of motor dysfunction in Parkinson's disease: an overview.

  2005cites this paper
• Optimising levodopa therapy for the management of Parkinson’s disease

  2005cites this paper
• Movement disorders in the older patient: differential diagnosis and general management.

  2005cites this paper
• Wearing-off 현상을 경험하는 파킨슨병 환자에서 엔타카폰의 효과 및 안정성 : 다기관 무작위 위약비교 이중맹검 연구

  2005cites this paper
• Optimising levodopa therapy for the management of Parkinson’s disease

  2005cites this paper
• Parkinson's disease: aetiology, diagnosis, and management.

  2005cites this paper
• An open-label evaluation of the tolerability and safety of Stalevo® (carbidopa, levodopa and entacapone) in Parkinson’s disease patients experiencing wearing-off

  2005cites this paper
• Progressive sleep 'destructuring' in Parkinson's disease. A polysomnographic study in 46 patients.

  2005cites this paper
• Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations

  2005cites this paper
• [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].

  2005cites this paper
• Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson’s Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study

  2004cites this paper
• Die fixe Kombination von Levodopa/Carbidopa mit Entacapon in der Parkinson-Therapie

  2004cites this paper
• COMT inhibitors in Parkinson’s disease

  2004cites this paper
• The role of COMT inhibition in the treatment of Parkinson’s disease

  2004cites this paper
• Safety and tolerability of COMT inhibitors

  2004cites this paper
• Clinical advantages of COMT inhibition with entacapone – a review

  2004cites this paper
• Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson’s patients

  2004cites this paper
• Frequency, Reasons, and Risk Factors of Entacapone Discontinuation in Parkinson Disease

  2004cites this paper
• Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo®)

  2004cites this paper
• Clinical Interventions in Aging Dovepress Levodopa in the Treatment of Parkinson's Disease: an Old Drug Still Going Strong

  year unknowncites this paper
• The efficacy of Levodopa+DDC inhibitor+Entacapone versus Levodopa+DDC inhibitor+Placebo in Parkinson's disease: an intervention review

  year unknowncites this paper